| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
YKL-06-061 targets salt-inducible kinases (SIKs), specifically SIK1, SIK2, and SIK3. It is a second-generation inhibitor that exhibits high potency and selectivity for these kinases. SIKs are involved in the regulation of various cellular processes including metabolism, inflammation, and transcription.
|
|---|---|
| ln Vitro |
YKL 06-061 increases the expression of MITF mRNA in a dose-dependent manner [1].
YKL-06-061 is a potent inhibitor of SIK1, SIK2, and SIK3 with IC50 values of 6.56 nM, 1.77 nM, and 20.5 nM, respectively. Its high potency and selectivity make it a valuable chemical probe for studying SIK biology and associated metabolic or transcriptional processes. The compound is used in research to investigate the role of SIKs in various diseases. |
| ln Vivo |
Specific in vivo activity data for YKL-06-061 are not extensively reported in the available literature. As a potent and selective SIK inhibitor, it is expected to exhibit efficacy in preclinical models of diseases where SIKs play a role, such as metabolic disorders and inflammation. Further research is needed to characterize its pharmacokinetic and pharmacodynamic profiles in animal models.
|
| Enzyme Assay |
The in vitro enzyme inhibition assay for YKL-06-061 typically involves measuring the kinase activity of recombinant SIK1, SIK2, and SIK3 using a standard kinase assay. The compound is incubated with the enzyme, a peptide substrate, and ATP, and the phosphorylation level is quantified to determine the IC50 value.
|
| Cell Assay |
RT-PCR[1]
Cell Types: UACC62 human melanoma cells and UACC257 human melanoma cells. Tested Concentrations: 0-4μM (UACC62); 0-16 μM (UACC257). Incubation Duration: 3 hrs (hours). Experimental Results: MITF mRNA expression increased in a dose-dependent manner. The in vitro cellular assay for YKL-06-061 typically involves culturing cells that express SIKs in appropriate growth media. Cells are treated with varying concentrations of the compound, and downstream signaling pathways or cellular responses are measured. The compound's effects on SIK activity and associated biological processes are assessed using Western blotting, ELISA, or other appropriate assays. |
| Animal Protocol |
In vivo animal studies for YKL-06-061 would typically involve the use of mouse models of metabolic disorders, inflammation, or other diseases where SIKs play a role. Animals would be administered the compound via appropriate routes (e.g., oral gavage or intraperitoneal injection) at various dose levels. Parameters such as metabolic markers, inflammatory markers, and histopathology would be assessed.
|
| ADME/Pharmacokinetics |
YKL-06-061 has a molecular weight of 527.66 g/mol and a molecular formula of C30H37N7O2. The IUPAC name is 1-Cyclobutyl-3-(2,6-dimethylphenyl)-7-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}-1H,2H,3H,4H-pyrimido[4,5-d][1,3]diazin-2-one. The compound is soluble in DMSO and has a purity of ≥98%. It should be stored as a powder at -25 to -15°C for up to 3 years.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for YKL-06-061 are not available in the public domain. The compound is intended for research use only and should be handled with appropriate laboratory safety precautions. Standard safety assessments would be required before any clinical application. Researchers should consult the safety data sheet for detailed handling and disposal information.
|
| References | |
| Additional Infomation |
YKL-06-061 is a potent and selective second-generation inhibitor of salt-inducible kinases (SIKs). It exhibits IC50 values of 6.56 nM for SIK1, 1.77 nM for SIK2, and 20.5 nM for SIK3. The compound is used as a chemical probe for studying SIK biology and associated metabolic or transcriptional processes. It has not yet entered clinical trials and is strictly for preclinical research purposes.
|
| Molecular Formula |
C30H37N7O2
|
|---|---|
| Molecular Weight |
527.660485982895
|
| Exact Mass |
527.3
|
| CAS # |
2172617-15-9
|
| PubChem CID |
132992144
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
39
|
| Complexity |
824
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1N(C2C(C)=CC=CC=2C)CC2=CN=C(NC3C=CC(=CC=3OC)N3CCN(C)CC3)N=C2N1C1CCC1
|
| InChi Key |
GVBAXIVNAHMIGH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C30H37N7O2/c1-20-7-5-8-21(2)27(20)36-19-22-18-31-29(33-28(22)37(30(36)38)23-9-6-10-23)32-25-12-11-24(17-26(25)39-4)35-15-13-34(3)14-16-35/h5,7-8,11-12,17-18,23H,6,9-10,13-16,19H2,1-4H3,(H,31,32,33)
|
| Chemical Name |
1-cyclobutyl-3-(2,6-dimethylphenyl)-7-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-4H-pyrimido[4,5-d]pyrimidin-2-one
|
| Synonyms |
YKL 06-061 YKL06-061 YKL-06-061
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~16.67 mg/mL (~31.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8952 mL | 9.4758 mL | 18.9516 mL | |
| 5 mM | 0.3790 mL | 1.8952 mL | 3.7903 mL | |
| 10 mM | 0.1895 mL | 0.9476 mL | 1.8952 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
